Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus

Surgical Infections

Volumn 9, Issue SUPPL. 1, 2008, Pages

  Napolitano, Lena M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; CYTOTOXIN; DALBAVANCIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; ICLAPRIM; LINEZOLID; MINOCYCLINE; ORITAVANCIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL STRAIN; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INTENSIVE CARE UNIT; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; TASTE DISORDER; TREATMENT FAILURE;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; INFUSIONS, PARENTERAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; SURGICAL WOUND INFECTION;

EID: 53749107338     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2008.063.supp     Document Type: Review

References (78)

1. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA; Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at http://198.246.98.21/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies. pdf. Accessed March 10, 2008. (//www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_04meeting. html.)
2. Kuo DC, Chasm RM, Witting MD. Emergency department physician ability to predict methicillin-resistant Staphylococcus aureus skin and soft tissue infections. J Emerg Med 2008 May 29 [Epub ahead of print].
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
4. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: Impact of antimicrobial therapy on outcome. Clin Infect Dis 2007;44:777-784.
5. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-268.
6. Garnacho-Montero J. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-2751.
7. Alvarez-Lerma F; ICU-Acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996;22:387-394.
8. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418-1423.
9. Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med 2006;34:2069-2074.
10. Chuck EA, Frazee BW, Lambert L, McCabe R. The benefit of empiric treatment for methicillin-resistant Staphylococcus aureus. J Emerg Med 2008 May 29 [Epub ahead of print]
11. Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007;44:483-492.
12. Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: Diagnostic approach and empiric treatment options. Cleve Clin J Med 2007;74(Suppl 4):S21-S28.
13. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-1406.
14. Adeyemi OA, Qi C, Zembower TR, et al. Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation. J Clin Microbiol 2008;46:2809-2813.
15. Fridkin SK, Hageman JC, Morrison M, et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-1444.
16. Daum RS. Skin and soft-tissue infections caused by methicillin resistant Staphylococcus aureus. N Engl J Med 2007;357:380-390.
17. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984.
18. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl):S368-S377.
19. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:2628-2630.
20. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-211.
21. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007;45:1705-1711.
22. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006;194:1761-1770.
23. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007;13:1418-1420.
24. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998;42:1303-1304.
25. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007;45:S184-190.
26. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006;42(suppl 1):S51-S57.
27. Awad SS, Elhabash SI, Lee L, et al. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: Reconsideration of empiric antimicrobial therapy. Am J Surg 2007;194:606-610.
28. Centers for Disease Control and Prevention. 12 Steps to Prevent Antimicrobial Resistance among Hospitalized Adults. CDC Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. Available at http://www.cdc.gov/drugresistance/healthcare/ha/12steps_HA.htm. Accessed August 2, 2006.
29. Daschner FD, Frank U, Kümmel A, et al. Pharmacokinetcs of vancomycin in serum and tissue of patients undergoing open-heart surgery. J Antimicrob Chemother 1987;19:359-362.
30. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-869.
31. Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988;32:1320-1322.
32. Luzzati R, Sanna A, Allegranzi B, et al. Pharmacokinetics and tissue penetration of vancomycin in patients undergoing prosthetic mammary surgery. J Antimicrob Chemother 2000;45:243-245.
33. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Therapeutic Drug Monit 2000;22:661-667.
34. Vancocin [package insert]. Exton, PA. ViroPharma Inc. 2005.
35. Zyvox [package insert]. New York, NY. Pfizer Inc. 2007.
36. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-77.
37. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-1846.
38. Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007;60:819-823.
39. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007;59:309-317.
40. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-1797.
41. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-394.
42. Weigelt J, Itani K, Stevens D, et al; Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-2266.
43. Weigelt J, Itani K, Stevens D, Knirsch C. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? Antimicrob Agents Chemother 2006;50:1910-1911.
44. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760-766.
45. Itani KMF, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005;26:442-448.
46. Schürmann D, Sorensen SV, De Cock E, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ 2008 Apr 24 [Epub ahead of print].
47. McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther 2007;29:469-477.
48. McKinnon PS, Sorensen SV, Liu LZ, Itani KMF. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006;40:1017-1023.
49. Sharpe JN, Shively, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Am J Surg 2005;189:425-428.
50. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: Results from a randomized clinical trial. Surg Infect 2003;4:57-70.
51. Tillotson GS, Draghi DC, Sahm DF, et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: Laboratory-based surveillance study. J Antimicrob Chemother 2008;62:109-115.
52. Narita M et al. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007;27:1189-1197.
53. Owens RC Jr, Lamp KC, Friedrich LV, Russo R. Postmarketing clinical experience in patients with skin and skinstructure infections treated with daptomycin. Am J Med 2007;120(10 suppl 1):S6-S12.
54. Cubicin [package insert]. Lexington, MA. Cubist Pharmaceuticals, Inc. 2007.
55. Arbeit RD, Maki D, Tally FP, et al.; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-1681.
56. Martone WJ, Lamp KC. Efficacy of daptomycin in skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: Results from the CORE Registry. Curr Med Res Opin 2006;22:2337-2343.
57. Davis SL, McKinnon PS, Hall LM, et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: Clinical and economic outcomes. Pharmacotherapy 2007;27:1611-1618.
58. Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50:1581-1585.
59. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000;44:2225-2229.
60. Tygacil [package insert]. Philadelphia, PA. Wyeth Pharmaceuticals Inc. 2007.
61. Ellis-Grosse EJ, Babinchak T, Dartois N, et al.; Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(suppl 5):S341-S353.
62. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-655.
63. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2974-2976.
64. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44.
65. Ceftobiprole (BAL5788) [Web site]. Basel, Switzerland: Basilea Pharmaceutica Ltd; 2008. Available at http://www.basilea.com/template_loader. php?tplpage_id=19&_function=render&id=1. Accessed January 3, 2008.
66. FDA issues approvable letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic [press release]. Basel, Switzerland: Basilea Pharmaceutica Ltd; March 18, 2008. Available at http://www.basilea.com/ template_loader.php?tplpage_id=34&mode=details&id=172. Accessed June 17, 2008.
67. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-3616.
68. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-1415.
69. Stryjewski ME, O'Riordan WD, Lau WK, et al.; FAST Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-1607.
70. Stryjewski ME, Chu VH, O'Riordan WD, et al.; FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-867.
71. Stryjewski ME, Graham DR, Wilson SE, et al. on behalf of the Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683-1693.
72. Targanta Therapeutics. Pipeline: Oritavancin program [Targanta. com Web site]. Available at http://www.targanta.com/pipeline/oritavancin.html. Accessed June 18, 2008.
73. Giamarellou H, O'Riordan W, Harris H, Owen S, Porter S, Loutit J. Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract]. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 14-17, 2003; Chicago, IL. Abstract L-739a.
74. Wasilewski MM, Disch DP, McGill JM, Harris HW, O'Riordan W, Zeckel ML. Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections (CSSI) [abstract]. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2001; Chicago, IL. Abstract UL-18.
75. Arpida provides comprehensive overview of pivotal phase III trial data [press release]. Reinach, Switzerland: Arpida Ltd.; April 17, 2008. Available at http://www.arpida.ch/users/1/content/arpida-assist-overview.pdf. Accessed April 18, 2008.
76. Arpida's Skin and Skin Structure Infection Study 1 (ASSIST-1). Phase 3 safety and efficacy study of IV iclaprim vs linezolid in cSSSI (ASSIST-1). Available at http://clinicaltrials.gov/ct2/show/NCT00299520?term= iclaprim+AND+skin &rank=1. Accessed June 18, 2008.
77. Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Invest Drugs 2008;9:210-225.
78. Arpida's Skin and Skin Structure Infection Study 2 (ASSIST-2). Study of intravenous (IV) iclaprim versus linezolid in complicated skin and skin structure infections [cSSSI] (ASSIST-2). Available at http://clinicaltrials.gov/ ct2/show/NCT00303550. Accessed June 18, 2008.